Literature DB >> 23616586

Electroencephalogram paroxysmal θ characterizes cataplexy in mice and children.

Anne Vassalli1, Jose M Dellepiane, Yann Emmenegger, Sonia Jimenez, Stefano Vandi, Giuseppe Plazzi, Paul Franken, Mehdi Tafti.   

Abstract

Astute control of brain activity states is critical for adaptive behaviours and survival. In mammals and birds, electroencephalographic recordings reveal alternating states of wakefulness, slow wave sleep and paradoxical sleep (or rapid eye movement sleep). This control is profoundly impaired in narcolepsy with cataplexy, a disease resulting from the loss of orexin/hypocretin neurotransmitter signalling in the brain. Narcolepsy with cataplexy is characterized by irresistible bouts of sleep during the day, sleep fragmentation during the night and episodes of cataplexy, a sudden loss of muscle tone while awake and experiencing emotions. The neural mechanisms underlying cataplexy are unknown, but commonly thought to involve those of rapid eye movement-sleep atonia, and cataplexy typically is considered as a rapid eye movement sleep disorder. Here we reassess cataplexy in hypocretin (Hcrt, also known as orexin) gene knockout mice. Using a novel video/electroencephalogram double-blind scoring method, we show that cataplexy is not a state per se, as believed previously, but a dynamic, multi-phased process involving a reproducible progression of states. A knockout-specific state and a stereotypical paroxysmal event were introduced to account for signals and electroencephalogram spectral characteristics not seen in wild-type littermates. Cataplexy almost invariably started with a brief phase of wake-like electroencephalogram, followed by a phase featuring high-amplitude irregular theta oscillations, defining an activity profile distinct from paradoxical sleep, referred to as cataplexy-associated state and in the course of which 1.5-2 s high-amplitude, highly regular, hypersynchronous paroxysmal theta bursts (∼7 Hz) occurred. In contrast to cataplexy onset, exit from cataplexy did not show a predictable sequence of activities. Altogether, these data contradict the hypothesis that cataplexy is a state similar to paradoxical sleep, even if long cataplexies may evolve into paradoxical sleep. Although not exclusive to overt cataplexy, cataplexy-associated state and hypersynchronous paroxysmal theta activities are highly enriched during cataplexy in hypocretin/orexin knockout mice. Their occurrence in an independent narcolepsy mouse model, the orexin/ataxin 3 transgenic mouse, undergoing loss of orexin neurons, was confirmed. Importantly, we document for the first time similar paroxysmal theta hypersynchronies (∼4 Hz) during cataplexy in narcoleptic children. Lastly, we show by deep recordings in mice that the cataplexy-associated state and hypersynchronous paroxysmal theta activities are independent of hippocampal theta and involve the frontal cortex. Cataplexy hypersynchronous paroxysmal theta bursts may represent medial prefrontal activity, associated in humans and rodents with reward-driven motor impulse, planning and conflict monitoring.

Entities:  

Mesh:

Year:  2013        PMID: 23616586     DOI: 10.1093/brain/awt069

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  21 in total

1.  Hypocretin (orexin) is critical in sustaining theta/gamma-rich waking behaviors that drive sleep need.

Authors:  Anne Vassalli; Paul Franken
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

2.  Narcolepsy Type 1 and Idiopathic Generalized Epilepsy: Diagnostic and Therapeutic Challenges in Dual Cases.

Authors:  Simone Baiardi; Stefano Vandi; Fabio Pizza; Lara Alvisi; Lucia Toscani; Elena Zambrelli; Paolo Tinuper; Geert Mayer; Giuseppe Plazzi
Journal:  J Clin Sleep Med       Date:  2015-11-15       Impact factor: 4.062

3.  GABAergic Neurons of the Central Amygdala Promote Cataplexy.

Authors:  Carrie E Mahoney; Lindsay J Agostinelli; Jessica N K Brooks; Bradford B Lowell; Thomas E Scammell
Journal:  J Neurosci       Date:  2017-02-24       Impact factor: 6.167

Review 4.  Sleep Neurophysiological Dynamics Through the Lens of Multitaper Spectral Analysis.

Authors:  Michael J Prerau; Ritchie E Brown; Matt T Bianchi; Jeffrey M Ellenbogen; Patrick L Purdon
Journal:  Physiology (Bethesda)       Date:  2017-01

5.  Hyperactivity and male-specific sleep deficits in the 16p11.2 deletion mouse model of autism.

Authors:  Christopher C Angelakos; Adam J Watson; W Timothy O'Brien; Kyle S Krainock; Thomas Nickl-Jockschat; Ted Abel
Journal:  Autism Res       Date:  2016-10-14       Impact factor: 5.216

Review 6.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

7.  Somatostatin+/nNOS+ neurons are involved in delta electroencephalogram activity and cortical-dependent recognition memory.

Authors:  Mark R Zielinski; Dmitriy N Atochin; James M McNally; James T McKenna; Paul L Huang; Robert E Strecker; Dmitry Gerashchenko
Journal:  Sleep       Date:  2019-10-09       Impact factor: 5.849

Review 8.  Reinventing polysomnography in the age of precision medicine.

Authors:  Diane C Lim; Diego R Mazzotti; Kate Sutherland; Jesse W Mindel; Jinyoung Kim; Peter A Cistulli; Ulysses J Magalang; Allan I Pack; Philip de Chazal; Thomas Penzel
Journal:  Sleep Med Rev       Date:  2020-03-20       Impact factor: 11.609

9.  Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function.

Authors:  Sawako Tabuchi; Tomomi Tsunematsu; Sarah W Black; Makoto Tominaga; Megumi Maruyama; Kazuyo Takagi; Yasuhiko Minokoshi; Takeshi Sakurai; Thomas S Kilduff; Akihiro Yamanaka
Journal:  J Neurosci       Date:  2014-05-07       Impact factor: 6.167

Review 10.  Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders.

Authors:  Shi-Bin Li; Jeff R Jones; Luis de Lecea
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.